Inventiva S.A. (IVA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Frederic Cren | Co-Founder, CEO & Director | 563.4k | -- | 1966 |
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer & Deputy CEO | 418.52k | -- | 1962 |
| Mr. Jean Volatier | Deputy GM & CFO | -- | -- | 1965 |
| Ms. Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer | -- | -- | 1971 |
| Mr. Eric Duranson L.L.M. | General Counsel | -- | -- | 1974 |
| Ms. Nathalie Harroy | Head of Human Resources | -- | -- | 1967 |
| Dr. Kristina Meyer Ph.D. | Executive VP and Business Development & Alliance Management | -- | -- | 1969 |
| Dr. Michael Cooreman M.D., Ph.D. | Chief Medical Officer | -- | -- | 1958 |
| Ms. Pascaline Clerc Ph.D. | Executive Vice President of Strategy & Corporate Affairs | -- | -- | 1980 |
Inventiva S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 114
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. It develops Lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was incorporated in 2011 and is headquartered in Daix, France.
Corporate Governance
Upcoming Events
March 26, 2025 at 3:00 PM UTC
Inventiva S.A. Earnings Date